Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 9/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | HTT | P42858 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22894774 | 0.81 | CXCR4 (0.35) | CXCR4NPSR1TSHRHTTMAPT | |
| SCHEMBL22894773 | 0.79 | SCN8A (0.33) | CYP1A2 | |
| SCHEMBL22894783 | 0.78 | NR1H2 (0.32) | CXCR4 | |
| SCHEMBL26693973 | 0.75 | DGAT1 (0.35) | HTTLMNAKMT2ACYP1A2CYP2D6 | |
| SCHEMBL3841245 | 0.68 | DGAT1 (0.33) | TSHR | |
| SCHEMBL22093251 | 0.68 | DGAT1 (0.34) | — | |
| SCHEMBL25129886 | 0.68 | MAPT (0.33) | MAPT | |
| SCHEMBL22894684 | 0.67 | CXCR4 (0.56) | CXCR4NPSR1TSHRMAPTCYP1A2 | |
| SCHEMBL2473549 | 0.67 | DGAT1 (0.34) | — | |
| SCHEMBL22894772 | 0.65 | HRH3 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210009557-A1 | ACYCLIC CXCR4 INHIBITORS AND USES THEREOF | X4 PHARMACEUTICALS, INC. | 2021-01-14 | — | — | US | disclosed |
| CN-111655261-A | Acyclic CXCR4 inhibitors and uses thereof | X4 制药有限公司 | 2020-09-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009557-A1 | ACYCLIC CXCR4 INHIBITORS AND USES THEREOF | CXCR4, CXCR3, CXCR1 | CXCR4 1/4885NPSR1 169/4885TSHR 1930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.